Dai­ichi and Zymeworks end an­ti­body pact af­ter sev­en years

Zymeworks and Dai­ichi Sankyo end­ed a sev­en-year col­lab­o­ra­tion on bis­pe­cif­ic an­ti­bod­ies last week.

Un­der the 2016 agree­ment, Zymeworks li­censed its Azy­met­ric and Efect plat­forms to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER